Literature DB >> 17255098

Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.

Roxanne A Vaughan1, Dhananjay S Sakrikar, M Laura Parnas, Steven Adkins, James D Foster, Romain A Duval, John R Lever, Santosh S Kulkarni, Amy Hauck-Newman.   

Abstract

The site of cocaine binding on the dopamine transporter (DAT) was investigated using the photoactivatable irreversible cocaine analog [125I]3beta-(p-chlorophenyl)tropane-2beta-carboxylic acid, 4'-azido-3'-iodophenylethyl ester ([125I]RTI 82). The incorporation site of this compound was mapped to transmembrane domains (TMs) 4-6 using epitope-specific immunoprecipitation of trypsin fragments and further localized using cyanogen bromide (CNBr), which hydrolyzes proteins on the C-terminal side of methionine residues. CNBr hydrolysis of [125I]RTI 82-labeled rat striatal and expressed human DATs produced fragments of approximately 5-10 kDa consistent with labeling between Met(271/272) or Met(290) in TM5 to Met(370/371) in TM7. To further define the incorporation site, substitution mutations were made that removed endogenous methionines and inserted exogenous methionines in combinations that would generate labeled CNBr fragments of distinct masses depending on the labeling site. The results obtained were consistent with the presence of TM6 but not TMs 4, 5, or 7 in the labeled fragments, with additional support for these conclusions obtained by epitope-specific immunoprecipitation and secondary digestion of CNBr fragments with endoproteinase Lys-C. The final localization of [125I]RTI 82 incorporation to rat DAT Met(290)-Lys(336) and human DAT I291M to R344M provides positive evidence for the proximity of cocaine binding to TM6. Residues in and near DAT TM6 regulate transport and transport-dependent conformational states, and TM6 forms part of the substrate permeation pathway in the homologous Aquifex aeolicus leucine transporter. Cocaine binding near TM6 may thus overlap the dopamine translocation pathway and function to inhibit TM6 structural rearrangements necessary for transport.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255098     DOI: 10.1074/jbc.M610633200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Authors:  David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Journal:  Bioorg Med Chem       Date:  2010-11-04       Impact factor: 3.641

2.  Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter.

Authors:  Michael J Tomlinson; Danielle Krout; Akula Bala Pramod; John R Lever; Amy Hauck Newman; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2018-08-17       Impact factor: 3.921

3.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

4.  A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

Authors:  David J Lapinsky; Shaili Aggarwal; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Roxanne A Vaughan
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

5.  Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Authors:  David J Lapinsky; Nageswari Yarravarapu; Tammy L Nolan; Christopher K Surratt; John R Lever; Michael Tomlinson; Roxanne A Vaughan; Howard M Deutsch
Journal:  ACS Med Chem Lett       Date:  2012-03-11       Impact factor: 4.345

6.  Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations.

Authors:  Xiaoqin Huang; Howard H Gu; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2009-11-12       Impact factor: 2.991

7.  Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.

Authors:  Kyle C Schmitt; Juan Zhen; Prashant Kharkar; Manoj Mishra; Nianhang Chen; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurochem       Date:  2008-09-11       Impact factor: 5.372

8.  Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.

Authors:  Rejwi Acharya Dahal; Akula Bala Pramod; Babita Sharma; Danielle Krout; James D Foster; Joo Hwan Cha; Jianjing Cao; Amy Hauck Newman; John R Lever; Roxanne A Vaughan; L Keith Henry
Journal:  J Biol Chem       Date:  2014-08-31       Impact factor: 5.157

9.  Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons.

Authors:  Michael Y Aksenov; Marina V Aksenova; Janelle M Silvers; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2008-06-19       Impact factor: 4.294

10.  How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation.

Authors:  Xiaoqin Huang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.